JMJD1C or the JMJD1C/RUNX1 interaction are such candidates for targeted therapies as JMJD1C is required for the survival of various leukemias but not for HSC homeostasis (Zhu et al., 2016). The gene discussed is JMJD1C; the disease is leukemia.